BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q3 2023 Earnings Call Transcript

Jon Stonehouse: Yes. I’m not going to get into the details today. All I’m going to tell you is don’t miss it. This is going to be different from other R&D days that you participated in and you’re going to get insight into our pipeline and how we discover drugs that I think is we’re pain.

Jinky Rosselli: Is a lot more than that [ph].

Operator: This concludes our question-and-answer session. I would like to turn the conference back over to Jon Stonehouse for any closing remarks.

Jon Stonehouse: Yes. Thank you. So today, it was all about ORLADEYO and our goal to give you better insight into what we see both today in the marketplace and the trends that we see in and then also how we see the market shaping up in the future. So hopefully, you found that very helpful. Tomorrow is all about the pipeline. And as Charlie said, it’s about how we’re expanding the pipeline and also how we’re discovering first-in-class and best-in-class molecules and then how we’ll be very careful and have clear no-go decisions around capital allocation. So please tune in. We’re really looking forward. We appreciate those of you that are making the track here to Birmingham, Alabama and look forward to talking to you tomorrow.

Operator: The conference is now concluded. Thank you for attending today’s presentation. You may now disconnect. Thank you.